U.S. drug company says new crown vaccine it developed is 94.5% effective
-
Last Update: 2020-12-15
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, U.S. pharmaceutical company Moderna said it had developed a new crown vaccine with an effective rate of 94.5 percent, based on early analysis of phase III clinical trials, U.S. media reported.
the company said preliminary analysis showed no significant safety risks to the vaccine and that tolerance was generally good.
in addition, Modner said the company's vaccine does not require ultra-low temperature storage, "the vaccine is expected to remain stable at 2 to 8 degrees Celsius standard refrigerator temperature for up to 30 days", "the vaccine can be stable at minus 20 degrees Celsius for up to 6 months; The
that Modner plans to apply to the U.S. Food and Drug Administration for emergency use authorization in the near future. By the end of 2020, the company expects to deliver 20 million doses of the vaccine to the U.S. market.
November 9th local time, BioNTech of Germany and Pfizer of the United States announced that preliminary results of a phase III clinical trial of its jointly developed new coronary mRNA vaccine showed that the vaccine was more than 90 percent effective in preventing healthy subjects from contracting the new coronavirus.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
